Sanofi Pasteur is expected to leverage Sutro’s cell-free protein synthesis technology in the production of two vaccine candidates.
Sutro Biopharma chief executive officer William Newell said the collaboration signifies the value of the company’s biochemical synthesis technology for the production of vaccines in addition to providing additional validation of the benefits of the technology platform.
"We are looking forward to expanding our expertise in protein expression into the field of vaccines with an established leader in the area," Newell added.
The details of the transaction were not revealed.
Four Oaks Partners served as an advisor to Sutro for the transaction.